$110.00Original price was: $110.00.$62.00Current price is: $62.00.
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that increases plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). DAC is an additive moiety that prolongs the plasma half-life of CJC-1295.
CJC-1295 with DAC is typically administered once or twice weekly due to its extended half-life of approximately 8–10 days. A common starting dose is 1 mg (0.5 ml) injected subcutaneously once per week. Depending on individual goals and clinical response, this may be titrated up to 2 mg (1 ml) weekly, either as a single injection or divided into two 1 mg doses given every 3–4 days.
The recommended protocol for beginners typically follows this format:
Week 1–2: 0.5 ml (1 mg) once weekly
Week 3–4: Increase to 1 ml (2 mg) weekly, either in one dose or split into two 0.5 ml doses
Week 5 and beyond: Maintain 2 mg weekly as tolerated and per desired outcome
The ideal time for injection is in the evening or before sleep, aligning with the body’s natural growth hormone secretion cycle. Injections should be administered subcutaneously in the abdomen or thigh, with site rotation to avoid irritation.
Each 10ml vial at 2mg/ml yields 20 mg total, allowing for 10 full 2 mg doses or 20 x 1 mg doses, depending on the dosing frequency.
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting analog of Growth Hormone Releasing Hormone (GHRH 1-29), engineered for sustained stimulation of endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) release. The inclusion of DAC significantly extends its half-life from minutes (as seen in native GHRH) to up to 8–10 days, allowing for less frequent dosing and more stable GH pulsatility.
CJC-1295 is often used to support:
Anti-aging and vitality protocols
Muscle recovery and lean mass development
Fat metabolism and body recomposition
Sleep quality, cognition, and skin health
Its unique structure enhances binding to albumin, reducing renal clearance and enabling prolonged biological activity.
CJC-1295 functions as a GHRH analog, binding to GHRH receptors in the anterior pituitary to stimulate endogenous growth hormone release. The addition of DAC extends its biological half-life by promoting covalent binding to albumin and reducing proteolytic degradation.
Key physiological actions include:
Increased amplitude and frequency of GH pulses
Subsequent elevation of circulating IGF-1 levels
Stimulation of protein synthesis and lipolysis
Promotion of lean muscle gain and fat metabolism
Improved cellular repair and collagen production
CJC-1295 with DAC does not inhibit the normal negative feedback mechanisms of GH secretion, preserving natural pulsatility while amplifying its effect.
There is no clinical safety data available for the use of CJC-1295 in pregnant or breastfeeding individuals. Due to the growth-promoting and hormonal effects of the compound, it is not recommended during pregnancy or lactation.
CJC-1295 is not approved for pediatric use. While it mimics natural GHRH and may theoretically benefit growth hormone-deficient children, it should only be considered under strict endocrinological supervision in such cases. Unsupervised use in children is contraindicated.
CJC-1295 (with or without DAC) is not FDA-approved as a therapeutic drug. It remains under clinical investigation and is available through compounding pharmacies and research outlets. It is not approved as a treatment for GH deficiency or related conditions.
